Rosmarinic acid reverses non‐small cell lung cancer cisplatin resistance by activating the MAPK signaling pathway

• DOI: 10.1002/ptr.6584
• Publication Date: 2020-01-27T12:23:31Z
• Authors: Xiao‐Zhong Liao; Ying Gao; Ling‐Ling Sun; Jia‐Hui Liu; Han‐Rui Chen; Ling Yu; Zhuang‐Zhong Chen; Wen‐Hui Chen; Li‐Zhu Lin
• Keywords: Rosmarinic acid

Cisplatin (DDP) is one of the first-line chemotherapeutic agents for non-small cell lung cancer (NSCLC). However, repeated use cisplatin in clinical practice often induces chemoresistance. The aims this study were to investigate whether rosmarinic acid (RA) could reverse multidrug resistance (MDR) NSCLC and explore underlying mechanisms. Our data demonstrated that RA significantly inhibited proliferation colony formation a dose-dependent manner, induced G1 phase cycle arrest apoptosis, increased sensitivity lines resistant DDP. Mechanistically, growth, arrested cycle, apoptosis by activating MAPK inhibiting expression P-gp MDR1, which correspondingly enhanced p21 p53 expression. We observed growth xenograft tumors derived from nude mice was combination therapy. demonstrate potentially effective MDR reversal agent NSCLC, based on downregulation MDR1 mRNA P-gp. Together, these results emphasize putative role as NSCLC.